Teresita M Bellido, PhD

Research Program: Cancer Biology Faculty Rank: Professor and Chair Campus: University of Arkansas for Medical Sciences College: College of Medicine Department: Physiology & Cell Biology

Cancer Research Interest

• Research Interest Statement: My research focuses on signal transduction in bone cells, with particular emphasis on the biology of osteocytes and on the direct action of hormones on bone cells. Past contributions elucidated the mechanisms of action of sex steroids, PTH, glucocorticoids, bisphosphonates, and mechanical stimuli in the regulation of bone remodeling and bone cell apoptosis. I currently lead studies on the regulation of osteocyte-derived genes by PTH; on the mechanisms by which PTH, Notch signaling, and canonical Wnt signaling regulate bone homeostasis through actions on osteocytes; on the mechanism of action of excess of glucocorticoids and diabetes in bone and muscle. I collaborate with other investigators on the role of nutrition on musculoskeletal health, the role of osteocytes in cancer in bone, and the endocrine functions of sclerostin. I am funded by the NIH since 1996 and by the Veterans Administration since 2008. I received NIH funding in the past to study the mechanisms by which IL-6 type cytokines regulate osteosarcoma cell growth. I am currently funded by the NCI with a multi-PI grant together with Dr. David Roodman from Indiana University in which I am the contact PI, to study the role of osteocytes in the musculoskeletal syndrome associated with multiple myeloma.

Contact Information

• Email Address: TMBELLIDO@UAMS.EDU
• Profiles Research Networking Software: View Profile

Active Grants

• National Science Foundation – Award ID 2217231
  “2022 Musculoskeletal Biology Workshop”
  Principal Investigator
  07/01/22 – 06/30/23
• NIH/Nat. Inst. on Aging – 1R01AG071332
  “PPARG regulates osteocyte function during aging”
  Principal Investigator
  09/30/21 – 05/31/26
• NIH/Nat. Inst. of Arthritis & Musculoskeletal & Skin Diseases – 7R01AR059357
  “Glucocorticoid-induced Atrophy in Bone and Muscle”
  Principal Investigator
  07/01/20 – 06/30/24

Publications

• Marino S, Akel N, Li S, [et al., including Bellido T]. Author Correction: Reversal of the diabetic bone signature with anabolic therapies in mice. Bone research. 2023 11(1):23. PMID: 37147286. PMCID: PMC10163036.
• Marino S, Akel N, Li S, [et al., including Bellido T]. Reversal of the diabetic bone signature with anabolic therapies in mice. Bone research. 2023 11(1):19. PMID: 37076478. PMCID: PMC10115794.
• Wang X, Ma Y, Chen J, [et al., including Bellido T]. A novel decellularized matrix of Wnt signaling-activated osteocytes accelerates the repair of critical-sized parietal bone defects with osteoclastogenesis, angiogenesis, and neurogenesis. Bioactive materials. 2023 21:110-128. PMID: 36093329. PMCID: PMC9411072.
• Williams JN, Irwin M, Li Y, [et al., including Bellido T]. Osteocyte-Derived CaMKK2 Regulates Osteoclasts and Bone Mass in a Sex-Dependent Manner through Secreted Calpastatin. International journal of molecular sciences. 2023 24(5). PMID: 36902150. PMCID: PMC10003151.
• Atkinson EG, Adaway M, Horan DJ, [et al., including Bellido T]. Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells Enhances PTH-Induced Bone Formation. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2023 38(1):70-85. PMID: 36321253. PMCID: PMC9825665.
• Xu X, Yang H, Bullock WA, [et al., including Bellido TM]. Osteocyte Estrogen Receptor ? (Ot-ER?) Regulates Bone Turnover and Skeletal Adaptive Response to Mechanical Loading Differently in Male and Female Growing and Adult Mice. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2023 38(1):186-197. PMID: 36321245. PMCID: PMC10108310.
• Ghassib I, Zhang H, Qi S, [et al., including Bellido T]. Off-target activity of the 8 kb Dmp1-Cre results in the deletion of Tsc1 gene in mouse intestinal mesenchyme. Transgenic research. 2022. PMID: 36547785.
• Clark A, Ghatak S, Guda PR, [et al., including Bellido T]. Myogenic tissue nanotransfection improves muscle torque recovery following volumetric muscle loss. NPJ Regenerative medicine. 2022 7(1):63. PMID: 36266362. PMCID: PMC9585072.
• Yuan X, Amin V, Zhu T, [et al., including Bellido TM]. Type I diabetes mellitus leads to gingivitis and an early compensatory increase in bone remodeling. Journal of periodontology. 2022. PMID: 35869905. PMCID: PMC9868190.
• Sabol HM, Amorim T, Ashby C, [et al., including Bellido T]. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia (New York, N.Y.). 2022 28:100785. PMID: 35390742. PMCID: PMC8990177.
• Delgado-Calle J, McAndrews K, Wu G, [et al., including Bellido T]. The Notch pathway regulates the bone gain induced by PTH anabolic signaling. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2022 36(3):e22196. PMID: 35137455. PMCID: PMC8855690.
• Chen J, Cuevas PL, Dworan JS, [et al., including Bellido T]. Wnt/?-catenin Signaling Controls Maxillofacial Hyperostosis. Journal of dental research. 2022:220345211067705. PMID: 35114849.
• Sabol HM, Ferrari AJ, Adhikari M, [et al., including Bellido T]. Targeting Notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer research. 2021. PMID: 34348968. PMCID: PMC8488008.
• Delgado-Calle J, Bellido T. The Osteocyte as a Signaling Cell. Physiological reviews. 2021. PMID: 34337974. PMCID: PMC8858675.
• Sato AY, Pellegrini GG, Cregor M, [et al., including Bellido T]. Skeletal protection and promotion of microbiome diversity by dietary boosting of the endogenous antioxidant response. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020. PMID: 33316081.
• Chen J, Yuan X, Pilawski I, [et al., including Bellido T]. Molecular Basis for Craniofacial Phenotypes Caused by Sclerostin Deletion. Journal of dental research. 2020:22034520963584. PMID: 33078679. PMCID: PMC7903846.
• Bellido T, Delgado-Calle J. Ex Vivo Organ Cultures as Models to Study Bone Biology. JBMR plus. 2020 4(3). PMID: 32161838. PMCID: PMC7059827.
• Davis HM, Deosthale PJ, Pacheco-Costa R, [et al., including Bellido T]. Osteocytic miR21 deficiency improves bone strength independent of sex despite having sex divergent effects on osteocyte viability and bone turnover. The FEBS journal. 2020 287(5):941-963. PMID: 31532878. PMCID: PMC7396683.
• Kegelman CD, Coulombe JC, Jordan KM, [et al., including Bellido TM]. YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular Remodeling. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2020 35(1):196-210. PMID: 31610061. PMCID: PMC7066596.
• Corry KA, Zhou H, Brustovetsky T, [et al., including Bellido T]. Stat3 in osteocytes mediates osteogenic response to loading. Bone reports. 2019 11:100218. PMID: 31440530. PMCID: PMC6700265.
• Zhao Y, Yuan X, Bellido T, Helms JA. A Correlation between Wnt/Beta-catenin Signaling and the Rate of Dentin Secretion. Journal of endodontics. 2019 45(11):1357-1364.e1. PMID: 31522810.
• Bullock WA, Hoggatt AM, Horan DJ, [et al., including Bellido T]. Lrp4 Mediates Bone Homeostasis and Mechanotransduction through Interaction with Sclerostin In Vivo. iScience. 2019 20:205-215. PMID: 31585407. PMCID: PMC6817631.
• Sato AY, Cregor M, McAndrews K, [et al., including Bellido T]. Glucocorticoid-Induced Bone Fragility Is Prevented in Female Mice by Blocking Pyk2/Anoikis Signaling. Endocrinology. 2019 160(7):1659-1673. PMID: 31081900. PMCID: PMC6591015.
• Rauner M, Baschant U, Roetto A, [et al., including Bellido T]. Author Correction: Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling. Nature metabolism. 2019 1(5):584. PMID: 32694850.
• Wu Y, Yuan X, Perez KC, [et al., including Bellido T]. Aberrantly elevated Wnt signaling is responsible for cementum overgrowth and dental ankylosis. Bone. 2019 122:176-183. PMID: 30408613. PMCID: PMC6559382.
• Delgado-Calle J, Kurihara N, Atkinson EG, [et al., including Bellido T]. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts. Oncotarget. 2019 10(28):2709-2721. PMID: 31105871. PMCID: PMC6505631.
• Alam I, Oakes DK, Reilly AM, [et al., including Bellido T]. Overexpression of WNT16 Does Not Prevent Cortical Bone Loss Due to Glucocorticoid Treatment in Mice. JBMR plus. 2019 3(4):e10084. PMID: 31044183. PMCID: PMC6478588.
• Saito H, Gasser A, Bolamperti S, [et al., including Bellido T]. TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone. Nature communications. 2019 10(1):1354. PMID: 30902975. PMCID: PMC6430773.
• Li JY, Yu M, Tyagi AM, [et al., including Bellido T]. IL-17 Receptor Signaling in Osteoblasts/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2019 34(2):349-360. PMID: 30399207.
• Rauner M, Baschant U, Roetto A, [et al., including Bellido T]. Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signaling. Nature metabolism. 2019 1(1):111-124. PMID: 30886999. PMCID: PMC6420074.
• Pacheco-Costa R, Davis HM, Atkinson EG, [et al., including Bellido T]. Reversal of loss of bone mass in old mice treated with mefloquine. Bone. 2018 114:22-31. PMID: 29879544. PMCID: PMC6056320.
• Davis HM, Aref MW, Aguilar-Perez A, [et al., including Bellido T]. Cx43 overexpression in osteocytes prevents osteocyte apoptosis and preserves cortical bone quality in aging mice. JBMR plus. 2018 2(4):206-216. PMID: 29978155. PMCID: PMC6029870.
• Delgado-Calle J, Hancock B, Likine EF, [et al., including Bellido T]. MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2018 32(5):2878-2890. PMID: 29401593. PMCID: PMC5901377.
• Kegelman CD, Mason DE, Dawahare JH, [et al., including Bellido TM]. Skeletal cell YAP and TAZ combinatorially promote bone development. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2018 32(5):2706-2721. PMID: 29401582. PMCID: PMC5901392.
• Sato AY, Peacock M, Bellido T. GLUCOCORTICOID EXCESS IN BONE AND MUSCLE. Clinical reviews in bone and mineral metabolism. 2018 16(1):33-47. PMID: 29962904. PMCID: PMC6022857.
• Ward LM, Bellido T, Kinnett K, Bonewald L. Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop: Morbidity due to osteoporosis in DMD: The Path Forward May 12-13, 2016, Bethesda, Maryland, USA. Neuromuscular disorders : NMD. 2018 28(1):64-76. PMID: 28756052.
• Delgado-Calle J, Anderson J, Cregor MD, [et al., including Bellido T]. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017 31(12):2686-2694. PMID: 28529307. PMCID: PMC5699973.
• Komaba H, Kaludjerovic J, Hu DZ, [et al., including Bellido T]. Klotho expression in osteocytes regulates bone metabolism and controls bone formation. Kidney international. 2017 92(3):599-611. PMID: 28396120.
• Davis HM, Pacheco-Costa R, Atkinson EG, [et al., including Bellido T]. Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging cell. 2017 16(3):551-563. PMID: 28317237. PMCID: PMC5418188.
• Ayus JC, Bellido T, Negri AL. Hyponatremia and fractures: should hyponatremia be further studied as a potential biochemical risk factor to be included in FRAX algorithms?. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2017 28(5):1543-1548. PMID: 28074251.
• Delgado-Calle J, Bellido T. New Insights Into the Local and Systemic Functions of Sclerostin: Regulation of Quiescent Bone Lining Cells and Beige Adipogenesis in Peripheral Fat Depots. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 32(5):889-891. PMID: 28370281. PMCID: PMC5489913.
• Maycas M, McAndrews KA, Sato AY, [et al., including Bellido T]. PTHrP-Derived Peptides Restore Bone Mass and Strength in Diabetic Mice: Additive Effect of Mechanical Loading. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 32(3):486-497. PMID: 27683064.
• Delgado-Calle J, Tu X, Pacheco-Costa R, [et al., including Bellido T]. Control of Bone Anabolism in Response to Mechanical Loading and PTH by Distinct Mechanisms Downstream of the PTH Receptor. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2017 32(3):522-535. PMID: 27704638. PMCID: PMC8502039.
• Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017 96:29-37. PMID: 27742498. PMCID: PMC5328835.
• Sato AY, Richardson D, Cregor M, [et al., including Bellido T]. Glucocorticoids Induce Bone and Muscle Atrophy by Tissue-Specific Mechanisms Upstream of E3 Ubiquitin Ligases. Endocrinology. 2017 158(3):664-677. PMID: 28359087. PMCID: PMC5460781.
• Pellegrini GG, Cregor M, McAndrews K, [et al., including Bellido T]. Nrf2 regulates mass accrual and the antioxidant endogenous response in bone differently depending on the sex and age. PloS one. 2017 12(2):e0171161. PMID: 28152064. PMCID: PMC5289572.
• He G, Shi Y, Lim J, [et al., including Bellido T]. Differential involvement of Wnt signaling in Bmp regulation of cancellous versus periosteal bone growth. Bone research. 2017 5:17016. PMID: 28607813. PMCID: PMC5460368.
• Sato AY, Cregor M, Delgado-Calle J, [et al., including Bellido T]. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2016 31(10):1791-1802. PMID: 27163932. PMCID: PMC8499032.
• Plotkin LI, Bellido T. Osteocytic signalling pathways as therapeutic targets for bone fragility. Nature reviews. Endocrinology. 2016 12(10):593-605. PMID: 27230951. PMCID: PMC6124897.
• Plotkin LI, Bellido T. Erratum: Osteocytic signalling pathways as therapeutic targets for bone fragility. Nature reviews. Endocrinology. 2016. PMID: 27469347. PMCID: PMC10132773.
• Pellegrini GG, Morales CC, Wallace TC, [et al., including Bellido T]. Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner. Nutrients. 2016 8(7). PMID: 27409635. PMCID: PMC4963899.